Patents
Sitemap › G01 - Measuring; Testing › G01N - Investigating or analysing materials by determining their chemical or physical properties › G01N 33 - Investigating or analysing materials by specific methods not covered by groups
Patents for G01N 33 - Investigating or analysing materials by specific methods not covered by groups (393,632)
06/2005
06/16/2005WO2005054822A1 Apparatus and method for determining the thickness of thin adhesive layers and seals
06/16/2005WO2005054814A1 Apoptosis-based evaluation of chemosensitivity in cancer patients
06/16/2005WO2005054812A2 Transportable automated onsite extraction apparatus
06/16/2005WO2005054811A2 Method and apparatus for ultrasonic determination of hematocrit and hemoglobin concentrations
06/16/2005WO2005054810A2 Polymorphic cd24 genotypes that are predictive of multiple sclerosis risk and progression
06/16/2005WO2005054551A1 Method and device for order management in a production process for a fibrous product
06/16/2005WO2005054510A2 Predicting response and outcome of metastatic breast cancer anti-estrogen therapy
06/16/2005WO2005054509A2 Assay and treatment
06/16/2005WO2005054501A1 Methods and devices for compound screening
06/16/2005WO2005054497A1 Method of screening immunological therapeutic drug for cancer
06/16/2005WO2005054496A1 Method of examining cell kinetics
06/16/2005WO2005054495A2 Ligand-containing micelles and uses thereof
06/16/2005WO2005054493A2 Altered activity of toll-like receptors
06/16/2005WO2005054469A1 Anti-sars monoclonal antibodies
06/16/2005WO2005054468A1 Target protein of antidiabetic agent and novel antidiabetic agent “insuful” corresponding thereto
06/16/2005WO2005054464A1 Fluorescent proteins
06/16/2005WO2005054458A1 Method for analyzing nucleic acid, cell for analyzing nucleic acid, and analyzer for nucleic acid
06/16/2005WO2005054427A2 Target sequences for synthetic molecules
06/16/2005WO2005054296A1 Antibodies recognizing methyllysine, process for producing the same and utilization thereof
06/16/2005WO2005054292A1 Compositions and methods related to a dimeric mhc class i and ii-like molecule (dsmhc i and dsmhc ii)
06/16/2005WO2005054290A2 Peptide hormones zalpha48 and zsig97
06/16/2005WO2005054283A2 Clp-protease as target for herbicides
06/16/2005WO2005054272A2 Human immunodeficiency virus entry inhibitor assay
06/16/2005WO2005053835A2 Artificial receptors including gradients
06/16/2005WO2005053796A1 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
06/16/2005WO2005053770A2 A self-condensing ph sensor
06/16/2005WO2005053751A1 Animal model for experimental allergic neuritis and uses thereof
06/16/2005WO2005053734A1 Use of limk-1, its analogues and ligands for the production of a medicament against a thrombus formation or blood clotting disease
06/16/2005WO2005053611A2 Treatment of phosphatidylinositol phospholipid disorders
06/16/2005WO2005053589A1 Endoscopic surgery device for the insertion and recovery of a haemostatic plug at the surgical site
06/16/2005WO2005053542A1 A respiratory monitoring, diagnostic and therapeutic system
06/16/2005WO2005053525A1 Improvements relating to hand held analytical devices
06/16/2005WO2005053505A2 Use of gene ncsag4 for the diagnosis and prevention of neosporosis and as a marker for analysis of the pathogenesis
06/16/2005WO2005053387A1 Non-human mammalian and non-mammalian animal models of age-related memory impairment
06/16/2005WO2005044293A3 Compositions able to prevent neurodegenerative processes and methods of assaying the same
06/16/2005WO2005043123A3 System and apparatus for body fluid analysis using surface-textured optical materials
06/16/2005WO2005040828A3 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
06/16/2005WO2005040807A3 Swiprosin-2 as a breast cancer marker
06/16/2005WO2005040789A3 Diagnostics and therapeutics for diseases associated with putative organic ion transporter okb1 (okb1)
06/16/2005WO2005037857A3 Method of protein analysis by maldi using protein fragmentation with peroxycarbonates
06/16/2005WO2005037440B1 Magnetic enrichment method, a reactor unit for micro particles and a magnet unit
06/16/2005WO2005037439A3 Method and a device for treating microparticles
06/16/2005WO2005033652A3 Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
06/16/2005WO2005032589A8 Prevention and treatment for gvhd
06/16/2005WO2005029068A3 Iconic colorimetric test device with reduced susceptibility to false positive and false negative readings
06/16/2005WO2005029035A3 Methods of screening compositions for g protein-coupled receptor agonist activity
06/16/2005WO2005029034A3 Methods for the identification of inhibitors of amidophosphoribosyltransferase and cutinase transcription factor 1 as antibiotics
06/16/2005WO2005028639A3 Environments that maintain function of primary liver cells
06/16/2005WO2005028613A3 Method for functionally screening agents which can modulate the activity of ubiquitine hydrolases and uses thereof.
06/16/2005WO2005027015A3 Method and system for quantitatively analyzing biological samples
06/16/2005WO2005024383A3 Methods employing combinatorial artificial receptors
06/16/2005WO2005023305A3 Modulating cell activity by using an agent that reduces the level of cholesterol within a cell
06/16/2005WO2005022146A3 Diagnostics and therapeutics for diseases associated with kallikrein 13 (klk13)
06/16/2005WO2005020840A3 Composition and method for marking procaine penicillin
06/16/2005WO2005017805A3 Systems and methods for predicting the structure and function of multipass transmembrane proteins
06/16/2005WO2005017522B1 Method for in vivo determination on tested animals of the efficient concentration of deuterium depleted water for cancer therapy
06/16/2005WO2005017179A3 Antibodies that recognize and bind phosphorylated human androgen receptor and methods of using same
06/16/2005WO2005016515A3 Colorable microspheres for dna and protein microarray
06/16/2005WO2005015203A3 Diagnostics and therapeutics for diseases associated with g protein-coupled opioid receptor mu 1 (oprm1)
06/16/2005WO2005014645A3 Pedf-r receptor and uses
06/16/2005WO2005014029A3 Use of dg008, dg065, dg210 or dg 239 secreted protein products for preventing and treating pancreatic diseases, obesity or metabolic syndrome
06/16/2005WO2005013899A9 Compositions and methods for the therapy and diagnosis of lung cancer
06/16/2005WO2005012549A3 Apparatus and methods for evaluating the barrier properties of a membrane
06/16/2005WO2005012505A3 Nanoparticle and microparticle based detection of cellular products
06/16/2005WO2005010167A3 Antibodies to the fbsa protein of streptococcus agalactiae and their use in treating or preventing infections
06/16/2005WO2005008557A3 The method of conducting and interpretation of clinical trials
06/16/2005WO2005008253A3 Stable compositions for measuring human natriuretic peptides
06/16/2005WO2005004800A3 Trypanosome derived apoptotic factors (taf)
06/16/2005WO2005003781A3 Secreted polypeptide species associated with cardiovascular disorders
06/16/2005WO2005003762A3 Diagnostics and therapeutics for diseases associated with sensory neuron-specific g protein-coupled receptor 2 (snsr2)
06/16/2005WO2005003154A8 Compositions and methods for the diagnosis and treatment of tumor
06/16/2005WO2004111227A3 Screening process for hydantoin racemases
06/16/2005WO2004111192A3 Targeted delivery to legumain-expressing cells
06/16/2005WO2004109255A3 Rapid screening of biogenic particles in collected aerosols
06/16/2005WO2004106936A3 Diagnostics and therapeutics for diseases associated with g protein-coupled p2y purinoreceptor 9 (p2y9)
06/16/2005WO2004106925A3 Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same
06/16/2005WO2004106367A3 Enterococcus antigens
06/16/2005WO2004103939A3 Assay method and apparatus
06/16/2005WO2004099782A3 Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39)
06/16/2005WO2004099383A3 Chromatographic assay system
06/16/2005WO2004096272A3 Methods and compositions for modulating the interaction between adiponectin and its receptor
06/16/2005WO2004094476A3 Compositions and methods relating to stop-1
06/16/2005WO2004094471A3 Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
06/16/2005WO2004092719A3 Gamma ray detectors woth coincidence circuit and their use for analyzing bulk materials
06/16/2005WO2004087281A3 Implementation of microfluidic components, including molecular fractionation devices, in a microfluidic system
06/16/2005WO2004083803A3 Test methods for determining the intracellular concentration of cyclic nucleotides
06/16/2005WO2004081199A3 Novel compositions and methods for the treatment of immune related disease
06/16/2005WO2004078913A3 Methods
06/16/2005WO2004074505A3 Method for determining functional sites in a protein
06/16/2005WO2004065936A3 Immunoglobulin e detection in mammalian species
06/16/2005WO2004065562A3 Endocan compositions and methods for the treatment of neoplasms
06/16/2005WO2004062472B1 System and method for in vitro bleeding time testing
06/16/2005WO2004060280A3 Methods and compositions for inhibiting the growth of hematopoietic malignant cells
06/16/2005WO2004047855A3 Proteins involved in the regulation of energy homeostasis
06/16/2005WO2004043238A8 Biomarkers for intra-amniotic inflammation
06/16/2005WO2004031727A3 Methods for diagnosing bone turnover disease
06/16/2005WO2003082072A3 Methods for selecting treatment regimens and predicting outcomes in cancer patients
06/16/2005WO2003018854A3 Immobilization of biological molecules onto surfaces coated with monolayers
06/16/2005US20050132448 Using streptomyces infected tubers as tools in diagnosing diabetes; macrolide antibiotic and onset of pancreatic disorders
06/16/2005US20050132428 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
1 ... 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 2114 2115 2116 ... 3937